Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 19.50 GBp
Change Today -1.12 / -5.45%
Volume 17.0K
VENN On Other Exchanges
As of 11:35 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

venn life sciences holdings (VENN) Snapshot

20.88 GBp
Previous Close
20.63 GBp
Day High
21.13 GBp
Day Low
19.50 GBp
52 Week High
01/26/15 - 26.25 GBp
52 Week Low
12/22/14 - 15.50 GBp
Market Cap
Average Volume 10 Days
-0.06 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

venn life sciences holdings (VENN) Related Businessweek News

No Related Businessweek News Found

venn life sciences holdings (VENN) Details

Venn Life Sciences Holdings plc, a clinical research organization, provides clinical trial management and resourcing solutions to pharmaceutical, biotechnology, and medical device clients in France, Germany, the Netherlands, the United Kingdom, Ireland, and Europe. It offers a range of clinical trial services, including protocol development, feasibility, investigator qualification and site selection, project management, medical monitoring, clinical monitoring of Phases I–IV, site management, patient recruitment, data management, biostatistics/data analysis, medical writing, pharmacovigilance regulatory services, organisation of investigator meetings, quality assurance, electronic data capture, IVRS/IWRS, and methodology consulting. The company was founded in 2012 and is based in London, the United Kingdom.

Founded in 2012

venn life sciences holdings (VENN) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €152.0K
Compensation as of Fiscal Year 2013.

venn life sciences holdings (VENN) Key Developments

Venn Life Sciences Holdings plc Announces Audited Consolidated Final Financial Results for the Year Ended 31 December 2014

Venn Life Sciences Holdings plc announced audited consolidated final financial results for the year ended 31 December 2014. For the year, revenue was €4,883,000 against €2,035,000 for the last year. Operating loss was €1,767,000 against €1,794,000 for the last year. EBITDA before exceptional items was €1,533,000 against €1,645,000 for the last year. Loss before income tax was €1,829,000 against €1,823,000 for the last year. Loss attributable to owners of the parent was €1,533,000 against €1,800,000 for the last year. Loss per ordinary basic and diluted share was €0.06 against €0.09 for the last year. Net cash used in operating activities was €1,028,000 against €1,859,000 for the last year. Purchase of property, plant and equipment was €99,000 against €31,000 for the last year. Losses in 2014 are principally attributable to the time lag between building a resource base and securing the necessary work to utilise the resource pool.

Venn Life Sciences Mulls Acquisitions

Venn Life Sciences Holdings plc (AIM:VENN) is actively screening acquisition opportunities in Central and Eastern Europe as clients request capability in this region and the operating cost differential could have a beneficial impact on profit margins.

Venn Life Sciences Expands its Service Offering with the Addition of Microbiology and Histology Services

Venn Life Sciences announced that InnoVenn, the skin science division of Venn, has expanded its service offering with the addition of Microbiology and Histology services. Innovenn offers clients in the cosmetic, personal care, medical device and pharmaceutical sectors tailor-made research programmes to develop skincare ingredients and products. The new services include the antimicrobial profiling of ingredients, investigation of pro and prebiotic effects on natural microflora and the quantitative microbiology of the skin. Innovenn's renowned team of experts carry out research using their leading human skin equivalent, Labskin, which allows for the direct testing of topical materials and formulations on a living skin surface. The company's Skin Histology laboratory provides services dedicated to cutaneous biology, including sample processing, imaging and evaluation. It is tightly integrated with the LabSkin in vitro skin model production and testing facility, enabling customers to conduct animal-free assessments of their ingredients and products for multiple parameters including irritation, penetration, UV damage, and antimicrobial activity. Innovenn has also recently expanded its workforce to deal with increasing international demand for their research and development services and the production of Labskin.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VENN:LN 19.50 GBp -1.12

VENN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VENN.
View Industry Companies

Industry Analysis


Industry Average

Valuation VENN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENN LIFE SCIENCES HOLDINGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at